| 1 | 1/1 | 返回列表 |
| 查看: 326 | 回復(fù): 0 | ||
霜葉金蟲(chóng) (小有名氣)
|
[求助]
求助一段摘要翻譯,謝謝
|
|
BACKGROUND: Motor response fluctuations and dyskinesias compromise long-term levodopa therapy in Parkinson's disease. Variations in plasma levodopa levels contribute to adverse reactions associated with chronic therapy. Therefore, sustained-release levodopa preparations may be associated with less motor fluctuations and a better outcome. We conducted a large, 5-year, multicenter study to address this hypothesis. METHODS: Six hundred and eighteen nonfluctuating patients with Parkinson's disease never exposed to levodopa therapy were randomized to (Sinemet CR 50/200) sustained-release or immediate-release (Sinemet 25/100) carbidopa/levodopa preparations in 35 centers worldwide. Dosage titration occurred over the 5 years of evaluations to maintain an optimal response. The primary endpoint, the 'event', was the presence of motor fluctuations, as defined by 20% 'off' time or 10% 'on' time with dyskinesias as recorded in the patient diary, or greater than or equal to a 50% positive response on the physician fluctuations questionnaire. Clinical rating scales, Nottingham Health Profile (NHP) and adverse reactions were also recorded. FINDINGS: During the 5 years of the study, both treatment groups responded extremely well to therapy. The incidence of all patients reaching the 'event' was low, approximately 20% by diary criteria and 16% by questionnaire definition, and there was no significant difference between the two treatment groups. Activities of daily living scores in the Unified Parkinson Disease Rating Scale (UPDRS) consistently favored the Sinemet CR treatment group and a number of the NHP scales also favored the CR group. Based upon the frequency of adverse experiences, and the overall low incidence of withdrawals, the two treatment groups demonstrated very similar safety profiles. The most common drug-related effect was nausea; seen in 20% of patients. Other drug-related effects were dizziness, insomnia, abdominal pain, dyskinesia, headache and depression. Drug-related withdrawals were less than 10% of all patients, primarily due to nervous/psychiatric complaints. INTERPRETATION: During a 5-year treatment period, control of parkinsonian symptoms was maintained by both immediate-release and sustained-release carbidopa/levodopa. Both treatment regimens were associated with a low incidence of motor fluctuations and dyskinesias. There was a statistically significant difference (p < 0.05) in activities of daily living as measured by the UPDRS in favor of Sinemet CR. |
| 1 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 化學(xué)308分求調(diào)劑 +7 | 你好明天你好 2026-03-23 | 8/400 |
|
|---|---|---|---|---|
|
[考研] 312求調(diào)劑 +9 | 上岸吧ZJY 2026-03-22 | 13/650 |
|
|
[考研] 0703化學(xué)一志愿南京師范大學(xué)303求調(diào)劑 +3 | zzffylgg 2026-03-24 | 3/150 |
|
|
[考研] 0856材料專(zhuān)碩353求調(diào)劑 +9 | NIFFFfff 2026-03-20 | 9/450 |
|
|
[考研] 321求調(diào)劑 +5 | 材料cailiao 2026-03-21 | 5/250 |
|
|
[考研]
材料調(diào)劑
5+4
|
想要一壺桃花水 2026-03-25 | 10/500 |
|
|
[考研] 北科281學(xué)碩材料求調(diào)劑 +17 | tcxiaoxx 2026-03-20 | 19/950 |
|
|
[考研] 334分 一志愿武理 材料求調(diào)劑 +4 | 李李不服輸 2026-03-26 | 4/200 |
|
|
[考研] 材料277求調(diào)劑 +5 | min3 2026-03-24 | 5/250 |
|
|
[考研] 309求調(diào)劑 +4 | gajsj 2026-03-25 | 5/250 |
|
|
[考研] 調(diào)劑310 +3 | 溫柔的晚安 2026-03-25 | 4/200 |
|
|
[考研] 一志愿中南大學(xué)化學(xué)學(xué)碩0703總分337求調(diào)劑 +7 | niko- 2026-03-22 | 7/350 |
|
|
[考研] 網(wǎng)絡(luò)空間安全0839招調(diào)劑 +4 | w320357296 2026-03-25 | 6/300 |
|
|
[考研] 0703化學(xué)求調(diào)劑 +6 | 奶油草莓. 2026-03-22 | 7/350 |
|
|
[考研] 340求調(diào)劑 +5 | 話梅糖111 2026-03-24 | 5/250 |
|
|
[考研] 化工專(zhuān)碩求調(diào)劑 +3 | question挽風(fēng) 2026-03-24 | 3/150 |
|
|
[考研]
|
13659058978 2026-03-24 | 4/200 |
|
|
[考研] 291求調(diào)劑 +5 | 孅華 2026-03-22 | 5/250 |
|
|
[考研] 298求調(diào)劑一志愿211 +3 | 上岸6666@ 2026-03-20 | 3/150 |
|
|
[考研] 材料學(xué)碩301分求調(diào)劑 +7 | Liyouyumairs 2026-03-21 | 7/350 |
|